-The Business Standard The new price caps for 191 essential drugs are likely to introduce serious distortions in the market for these medicines The National Pharmaceutical Pricing Authority, or NPPA, has announced new price caps for 191 essential drugs that are 10 to 50 per cent lower than the current prices. Drug makers have 45 days to recall the earlier batches and send out new ones with the lower price tags. This...
More »SEARCH RESULT
Total Matching Records found : 56
Why Orissa mining may not go the Goa way -Meera Mohanty
-The Economic Times Three weeks ago, when the Supreme Court reopened the iron-ore mining door some more in Karnataka, miners in Orissa breathed a Rs 50,000 crore sigh of relief. Also in the dock for some offences of a similar nature, Orissa's iron-ore miners, who produce a third of this mineral that is critical to steel, had been dreading their fate, which lay in the hands of a Central government panel. The...
More »HIV, cancer patients seek access to affordable medicines-Aarti Dhar
-The Hindu Protesters see attempt by EU to undermine Indian judiciary in the EU-FTA pact People living with HIV, cancer patient groups and public health activists came out on the streets on Wednesday demanding that India reject the European Union's demands in the European Union-India Free Trade Agreement (EU-India FTA) negotiations. The protests coincide with Prime Minister Manmohan Singh's visit to Germany to meet Chancellor Angela Merkel with the FTA on top of...
More »More battles in store-Aarti Dhar
-The Hindu Well before the Supreme Court rejected Novartis' application for patent for Glivec (Gleevec in the U.S.), drawing attention to the dichotomy of generic and patented drugs, activists have been demanding access to expensive drugs used in the treatment of cancer, hepatitis C and serious HIV. Trastuzumab is one such, used in the treatment of HER2+ type of breast cancer, which affects about one in four patients with the disease. Rough...
More »YK Sapru, founder chairperson of Cancer Patients Aid Association (CPAA) interviewed by Sushmi Dey
-The Business Standard Interview with Founder chairman of Cancer Patients Aid Association Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting. Sapru, founder chairman of Cancer Patients Aid Association, or CPAA (which moved the Supreme Court to keep the prices of the cancer drug low), tells Sushmi Dey what the judgment means to cancer patients....
More »
